Transgene

Transgene Net Debt / EBITDA

The Net Debt to EBITDA of Transgene (TNG.PA) as of Nov 18, 2026 is 0.19. In the previous year, Net Debt to EBITDA was -0.05 — a change of -446.89% (higher).

Net Debt / EBITDA

0.19

YoY

-446.89%

Last updated:

Net Debt to EBITDA of Transgene is 2024 0.19 . Net Debt to EBITDA of Transgene was 2023 -0.05 . It decreases by -446.89% higher compared to the previous year.

The Transgene Net Debt / EBITDA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Net Debt / EBITDA
Date
Net Debt / EBITDA
Jan 1, 2017
-0.03 EUR
Jan 1, 2018
0.88 EUR
Jan 1, 2019
1.16 EUR
Jan 1, 2020
0.96 EUR
Jan 1, 2021
2.11 EUR
Jan 1, 2022
0.47 EUR
Jan 1, 2023
-0.05 EUR
Jan 1, 2024
0.19 EUR
The Transgene Net Debt / EBITDA history
YEARNet Debt / EBITDAYoY
0.19-446.89%
-0.05-111.47%
0.47-77.63%
2.11+120.67%
0.96-17.99%
1.16+32.63%
0.88-3,077.60%
-0.03-105.48%
0.54-389.69%
-0.19-119.61%
0.95-229.57%
-0.73+42.60%
-0.51+98.05%
-0.26-34.62%
-0.40-23.25%
-0.52-22.46%
-0.67+1,140.50%
-0.05+50.87%
-0.04-45.70%
-0.07—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Transgene Stock analysis

What does Transgene do? Transgene SA is a French biotechnology company specializing in the development and production of therapeutics, with a focus on cancer medications. It has a strong patent portfolio in the field of viral vectors, which are used for targeted gene therapy. The company's main areas of operation are clinical trials, research, and production. Transgene has research and production facilities in Strasbourg and Lyon, with over 100 employees. It has established partnerships with pharmaceutical companies, including Takeda Pharmaceuticals, for the development and marketing of therapeutics. Its flagship product, OncoVir-1®, is an immunomodulator that stimulates the immune system to fight tumor cells. Another promising product is TG4010, a therapeutic vaccine for non-small cell lung carcinoma. Transgene is an emerging company with a promising portfolio of cancer therapeutics, leveraging its expertise in viral vectors and collaborating closely with industry partners to expedite the development of marketable products. Transgene is expected to play a significant role in the development of new and innovative cancer treatments. Transgene is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Transgene stock

Net Debt to EBITDA of Transgene is 0.19 in 2024.

Net Debt to EBITDA of Transgene changed from -0.05 to 0.19, representing a -446.89% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Net Debt to EBITDA Transgene since 2006 – with annual values, charts, and detailed analysis.

Net Debt/EBITDA measures how many years it would take to repay all debt using EBITDA. Lower ratios indicate stronger debt repayment capacity.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Net Debt to EBITDA's Transgene with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — Transgene

All Key Metrics — Transgene